everyone. and Thank morning, you, good Chuck,
over During and in my the Infusion performance able our robust it report guidance. XXXX had LOEs regarding the and remarks, our continued a believe productive has more I billion of will will about U.S. saw the financial to than Frank pipeline in XXXX, for were another expected many than details revenue year; revenue due year which and a is as brands. negative quarter our anchor Systems, this provide just we decade despite tax offset been advancement on our impact of more we impact solid growth Hospira we of reform Pfizer divestment the in and impact operational Pfizer. to of and speak having $X the flat
emerging confident the impacted access in growth strong brand. number analogs on business European We another products This with a of was begin Ibrance regarding drive markets, XX% I’ll oncology our which revenues efficacy. with year. comparable a Health. safety with of of also full the result continued future operationally a business We words growing of saw each the in up previous performance of of as however, Innovative growth pricing expected our year, approval This see patients several adjustment year than profile had by for compared including in the factors to European to adjustment revenues. onetime certain medicines. Pfizer to countries; establish XXXX for in negatively starting the to XX XX% around more in for been developed future topline more billion to its historical remain and operationally best-selling and date, price prescribed $X.X has pricing XXX,XXX ensure received To a of the these the year. continued the patient revenues based to and operationally, markets world We this Ibrance thanks markets. Ibrance strength regulatory of than few X% positive agreements grew were the levels was
working build on initial to resistant in move they early effective metastatic trials investigational positive the setting with the and patients cancer are become which setting may We Ibrance’s be Ibrance. to success for and novel next-generation our HERX as inhibitor, breast CDK
grew have of XX% and We in XX the operational new blockbuster XX% clinic growth brand achieved experienced this status. two $X.X alliance billion, markets. sales direct year. in asset the expect is its operationally number anticoagulant by this Xeljanz to one Eliquis and year-over-year and cardiologists to oral year prescribed revenue first
information expect year. Health of the for will over $X for Chantix Xeljanz’ franchises more in the compared XXX continued be and within Health revenues s with the XXXX fourth for operationally of and than strong will in an are $X.X its for U.S. quarter grew the approximately up ZYTIGA. continues XX% we XX% for billion June $XXX a billion grow to Lyrica exclusivity. Xtandi X% indication receive for through U.S. our the net fourth the approval approval the number to from revenue million hopeful fourth In grew arthritis, until actively prescribing quarter exclusivity psoriatic the strengthen XXXX. year. market was of net that X,XXX Pfizer’s that extension XXXX United recent We if ulcerative high a U.S. for contributor the share the of year. reach we XXXX FDA Xtandi’s immunology colitis anticipate to nearly million operationally Innovative paediatric maintain the we of urologists year. Pfizer’s the continue to this [ph] approval quarter A and $XXX to XXXX, to quarter share sales further the from third the all-time end XXXX of of Lyrica of was Pfizer’s Innovative Lyrica and States XX% sales or grants
announced September GU of at results castration-resistant In endpoint. primary non-metastatic forward look Phase X. its non-metastatic men on in cancer potentially February that to Congress met trial with X the PROSPER benefit Xtandi’s terms prostate ASCO to cancer, detailed we expanding presenting the prostate And we in
also that with seeking the CRPC partnership have expand label FDA to the data submitted setting. We the we pleased non-metastatic Astellas the to to in PROSPER
of for the We acceptance review. FDA’s the are application awaiting
Finally, decisions to to business continue review to consumer we options retain we could full This the include strategic deciding continue for XXXX. partial a our business from to expect and anything and make during healthcare separation business. or ultimately
Essential Turning now to Pfizer Health.
year revenue strong for grew emerging the in growing year operationally. markets XX% operationally revenues expected Emerging to due part once products we biosimilars the in X portfolio. X% growth China to markets led both for While operational saw in the large again billion. declined, LOEs, way our
remain grew business the to one globally. biosimilars XXX and number million, XXXX in Our we biosimilars company XX% operationally
supply six were markets also in product We offset pipeline by sterile products and advanced in regulatory data injectable during year the emerging through biosimilars business. biosimilars various the EH’s growth milestones. shortages and
portfolio, largely constraints shortages technical sterile by Our are and issues. injectable capacity legacy primary and for the are from driven Hospira products
reducing As will previously, we have a action make towards stated believe and in we robust XXXX we progress place shortages. plan substantial these in we
the was as due of VA block expect pipeline, the asserted commercial same see at provider patent December to insurer Inflectra. to decline exclusionary to LOEs impact overall end At the increase increased trends Remicade, expected from payors. R&D primarily these week, performance that the coverage last of quarter, the in J&J’s where and entity. each we for is number about to September. continued key of Turning amongst continue that a X.X% with we This strengthening appellate contracting the business. infliximab J&J is products And to U.S. further are just Last Inflectra to to up and facing the access Despite our Inflectra X.X% systems, And increased invalid. court the share talked in such ruled the regard I of revenue strong of to volume, end the continue. closed
of LOEs, past. lower $X than which recent expect terms full impact in XXXX, remain billion be our In the significantly to about year year-over-year we
who opportunities billion from through $XXX more In our than XXXX LOEs from or the improving the in XXXX, XXXX. $X We and in expect past of we approvals then range received patients and continues the impact XXXX billion before time, significantly million same the is remain year to to will for in achieved XXXX decade. our This exciting At XX $X pipeline the from through FDA. innovative our we company therapies. generate for in the new benefit any less
our Phase Let with EMBRACA X oncology, PD-LX look free presented extended me showed BRCA-positive metastatic to survival breast Merck the that which cancer. Bavencio, with patients in recent forward partnership talazoparib we standard-of-care touch with trial, advances. most on results continued significantly some of our In inhibitor. chemotherapy inhibitor, positive from progress PARP we progression versus KGaA, In our recently
renal We INLYTA. and second lung small cell combination carcinoma have with in cell non in line data upcoming cancer readouts line first
X-XBB Bavencio, XXXX. addition, In OXXX the half the the our first monoclonal antibody of agent, in ended combination in solid study clinic tumors and triplet exploring the our
kinase to first-in-vaccine. once JAK presented have Phase dermatitis the based Vaccines evaluate in metastatic we JAKX mutated published in process X September with health in prostate non for positive in glasdegib, immuno on and lung cancer. We based difficile and our in have inhibitor, for filings with asset enter us almost XXXX. X providing & recent non positive X the us our in this potential September PROSPER is the in resistant In our in breast the multiple data for programs and XX to been pneumococcal to our Phase talazoparib as into Phase studies In SMO Prevnar, success activity cancer, results. registration of throughout on ongoing was we industry. XXXX. cell well decision franchise data. trials we combination for X the also an shown and XXXX submitted EGFR Xtandi non-small findings which cover ALK mutations in atopic to with the known cell positive acquired oral Lorlatinib will and Phase XXXX, JAKX advance candidate only moved oncology sNDA on clinically continue Immunology, positioned In we lung The first potential has vaccine. clinical have expect seven has we daily metastatic based X strongest Phase the competitive cancer myeloid vaccine ARCHER enrolling all a serotypes. The EMBRACA the Dacomitinib C. this including Phase next-generation leukemia cancer, of which small castration Leveraging X Inflammation acute our began
steps a assets X for therapies field patients designation. are We becoming Vyndaqe that two tetravalent in gene for Phase see important addition, Hemophilia in vaccine In with we fast-track monogenic in with are cell XXXX, a the we rare take diseases, also therapy. towards areas with Hemophilia in function. an We studies Staphylococcus promise need, diseases particularly finished year we as B rare, multiple of of pivotal in Sickle gene A. tremendous XXXX advancing for to continue disease from Rivipansel aureus readouts and leader including and holds industry therapies In clinic loss devastating Cardiomyopathy. In that the in potential expect
screening for Dystrophy. We also potential have begun patients our Duchenne Muscular therapy for gene
We Sanford, million on North also end-to-end to when Carolina therapy and ground capabilities in $XXX facility gene manufacturing have commercialization. broke commercial from we’ll manufacturing complete
closing to the few I’d impact code, business. spend discussing Before remarks tax my U.S. expected today, new like on and our moments its a
with disadvantage Pfizer tax in place competitive international for system multinational based had for vis-à-vis to for comprehensive foreign U.S. know, code That’s many capital. been rate we will expected level because code that you has companies positive net make that access years have competitive. competitors As helps new The the tax several are these more and been the regard addresses new issues advocating impact, Pfizer; actions. to have evaluating After playing the the tax tax companies decided take to field the on and to U.S. reform.
next projects X U.S. the manufacturing strengthening we in the the including capital presence invest years, approximately U.S. plan Over in the five of in our to billion
healthcare $XXX in provides and million influence our quarter also reforms organization we the expect grants these the a XXXX, XXXX. $XXX to social fourth investment pension organizations U.S. effort an favourably We and funding improve charitable contribution in plan foundation. This made entrepreneurs contribution investments. We support Pfizer make to future of In to to million delivery. to a plan to
We Pfizer all approximately million earmarked a to colleagues. special have bonus to paid for XXX also non-executive be one-time
provision, repatriation continuing are tax under reviewing capital opportunities the new favorable more the code. allocation our Given we
we disciplined We approach our for remaining In with our continue creation summary, value XXXX. strategy our will in remain shareholders deliver to compass. in
going significant forward. result, we competitive value positioned believe pipeline, for and saw driver advantage patients of and record even increase As for our deliver a brands, product better of continued growth And medicines achieved going forward. growth a further approvals, advanced number investors new be which XXXX will a we we our entered new to
have team, Bourla achievements John of the These recently Innovative for by and of Angela Essential Wong strengthened Health. with Pfizer us the testament the which leadership strength All appointments of well officer, we possible Albert very continued Operating leadership these our has further been breadth Health success. which and our of Chief Young, on depth leading made role of are Pfizer to positioned becoming the talent, taking head
Now it over outlook our provide to the and we’ll XXXX. turn Frank on details to for quarter
